Prevention of SHIV transmission by topical IFN-β treatment

RS Veazey1, HA Pilch-Cooper2, TJ Hope3, G Alter4, AM Carias3, M Sips4,5, X Wang1, B Rodriguez2, SF Sieg2, A Reich6, P Wilkinson2, MJ Cameron7 and MM Lederman2

Understanding vaginal and rectal HIV transmission and protective cellular and molecular mechanisms is critical for designing new prevention strategies, including those required for an effective vaccine. The determinants of protection against HIV infection are, however, poorly understood. Increasing evidence suggest that innate immune defenses may help protect mucosal surfaces from HIV transmission in highly exposed, uninfected subjects. More recent studies suggest that systemically administered type 1 interferon protects against simian immunodeficiency virus infection of macaques. Here we hypothesized that topically applied type 1 interferons might stimulate vaginal innate responses that could protect against HIV transmission. We therefore applied a recombinant human type 1 interferon (IFN-β) to the vagina of rhesus macaques and vaginally challenged them with pathogenic simian/human immunodeficiency virus (SHIV). Vaginal administration of IFN-β resulted in marked local changes in immune cell phenotype, increasing immune activation and HIV co-receptor expression, yet provided significant protection from SHIV acquisition as interferon response genes were also upregulated. These data suggest that protection from vaginal HIV acquisition may be achieved by activating innate mucosal defenses.

INTRODUCTION

Defining the innate mucosal defenses that may prevent mucosal HIV transmission is a high priority.1,2 The determinants of protection against HIV infection are, however, poorly understood. Certain alterations of host elements are known to be protective against HIV transmission. For example, a recognized 32 base pair deletion in the open reading frame of the gene encoding the HIV co-receptor CCR5 (d32) when present in the homozygous state confers nearly complete protection against HIV acquisition.3–5 Likewise topical blockade of CCR5 using modified chemokine analogs or allosteric CCR5 inhibitors can protect non-human primates from infection with simian human immunodeficiency virus (SHIV) infection.6–8 Nonetheless, most persons at apparent high risk for HIV acquisition who have remained uninfected do not have recognized polymorphisms in CCR5 or its ligands.9–11 Thus other mechanisms may exist that provide relative protection against HIV acquisition. Increasing evidence suggest that innate immune defense mechanisms may be involved in the protection of mucosal surfaces from HIV transmission in highly exposed, uninfected patients.1

The type 1 interferons including IFN-α and IFN-β comprise a class of endogenous host elements that were first recognized for their ability to “interfere” with the replication of viruses in vitro (reviewed in ref. 12). This class of molecules induces resistance to HIV through a number of mechanisms that include activation of several defined host factors that restrict HIV replication.13 Also type 1 interferons are capable of enhancing antiviral defenses through activation of cytolytic cells and enhancing the maturation of adaptive immune defenses.14 Type 1 interferons are expressed and secreted in response to viral infection or recognition of pathogen-associated molecular patterns. Following the engagement of these cytokines with the interferon receptor, the expression of a large number (> 900) of interferon...
response genes (IRGs) with diverse functions may be induced to generate an antiviral state (reviewed in ref. 12).

We hypothesized that type 1 interferons might be capable of mediating protection from acquisition of HIV and therefore applied a recombinant type 1 interferon (IFN-β) to the vagina of rhesus macaques, then vaginally challenged animals with pathogenic Simian–human immunodeficiency virus containing human env and reverse transcriptase genes (RT-SHIV). Here we show that topical administration of recombinant human β-interferon to mucosal tissues results in local changes in immune cell phenotype and activation, yet results in significant protection against RT-SHIV acquisition. This was not likely related to effects on the HIV co-receptor CCR5, as CCR5 density actually increased on mucosal and lymphoid T cells in animals that had been treated with IFN-β. These data suggest that protection from vaginal HIV infection may be achieved by activating vaginal innate defenses.

RESULTS

IFN-β treatment rapidly induces T-cell activation, and increased numbers of CD4 + CCR5 + T cells and macrophages in the vaginal mucosa

To assess the effects of topical IFN-β application on local immune responses, we first treated six female macaques intravaginally with either low- (1.2 × 10^5 units ml^−1; n = 2), intermediate- (6 × 10^5 units ml^−1; n = 2), or high-dose (3 × 10^6 units ml^−1; n = 2) recombinant human IFN-β (Rebif, Pfizer, New York, NY) Two controls received topical saline only. We used this type and dose of interferon as our preliminary data (not shown) indicated that IFN-β is among the most active of 12 different type 1 interferons in inhibiting HIV replication in human peripheral blood mononuclear cell (PBMC), and doses this high (and greater) have been well-tolerated when applied intranasally in humans.15 Two days later each macaque was dosed intravaginally with 2 ml of saline or IFN-β using the same concentrations as initially. Six hours later, all eight animals were humanely euthanized. At necropsy, female reproductive tissues (FRT) were carefully examined for evidence of inflammation, but no visible lesions were detected. Vaginal tissues were processed for flow cytometry, immunohistochemistry, and RNA sequencing (RNA-Seq).

Compared with controls, all six IFN-β-treated macaques had significantly higher numbers of CD4 + T cells and macrophages in vaginal mucosa (Figure 1). Increased CD4 + T-cell densities were detected in the epithelium, and in the lamina propria (Figure 1a,b). Similarly, a marked, dose-dependent increase in macrophages was evident in the vaginal mucosa (Figure 1). By flow cytometry, vaginal mucosal CD4 + T cells of IFN-β-treated animals had higher expression of HLA-DR and CCR5 (Table 1, Supplementary Figures S1 and S2 online), indicating these infiltrating CD4 + T cells were more activated, expressing higher levels of the HIV co-receptor CCR5, and thus potentially better targets for SHIV infection. Similarly, higher expression of HLA-DR and CCR5 was detected on CD8 + cells in vaginal tissues of IFN-β-treated macaques (Table 1). Increased expression of Caspase 3 was also detected in both CD4 + and CD8 + vaginal T cells (Table 1). No significant changes were detected in expression of HLA-DR, CD38, or CCR5 on peripheral blood T cells (not shown).

Topical IFN-β treatment protects macaques from vaginal SHIV transmission

We then performed a series of topical vaginal IFN-β dosing and SHIV challenge experiments to determine whether repeated dosing could protect macaques from vaginal SHIV acquisition. Macaques were intravaginally dosed with IFN-β, or saline placebo and 4 h later, all were intravaginally challenged with SHIV. One and two days after initial dosing, vaginal IFN-β or placebo dosing was repeated; this dosing and challenge regimen was repeated weekly for 5 weeks. In total, we performed this series of repeated vaginal IFN-β dosing and viral challenge studies in 15 female macaques treated with high-dose 3 × 10^6 U ml^−1 IFN-β for comparison with 14 mock-treated controls. Nine of the 15 IFN-β-treated macaques were completely protected from infection, whereas only 2/14 control animals escaped infection (Figure 2). These differences were significant by Fisher’s exact test (P < 0.015). Note: 8/14 controls (57%) and 4/15 (26%) high-dose IFN-β-treated animals were infected by the fourth challenge (Figure 2). Also, the 6 IFN-β-treated animals that became infected showed a trend for lower peak viral loads compared with the controls (Figure 3), but these results were not significant. In summary, a significant (P < 0.015) level of protection from vaginal SHIV transmission was afforded to animals by repeated dosing with topical IFN-β.

Although topical application of IFN-β lowered the frequency of vaginal transmission, the mechanisms behind this protection are unclear. Our initial studies showed topical IFN-β resulted in an increase in absolute numbers, co-receptor expression, and activation of vaginal CD4 and CD8 T cells (Table 1). Activation was characterized more by increased HLA-DR expression than CD38 expression (Table 1, Supplementary Figures S1 and S2). Increased CCR5 expression was also observed in the initial study suggesting either that IFN-β exposure activated resident cells or enhanced the influx of activated co-receptor expressing immune cells or both. An increase in Caspase 3 + , CCR5 + T cells also suggests that IFN-β exposure increased cellular activation. Conceivably, the activation of Caspase 3 by interferon resulted in the early death of cells that are plausibly good targets for HIV infection, thereby balancing or abrogating the effects of increasing target cell frequency, though some studies suggest IFN-induction of Caspase 3 may activate cells without driving cell death.16,17

Topical IFN-β treatment results in marked upregulation of inflammatory and myeloid activation genes

The above data suggest topical IFN-β was inducing a local protective host defenses despite increasing the pool of potentially susceptible target cells for SHIV infection. To test the hypothesis that IFN-β exposures drives expression of host IRGs that promote an overall innate antiviral state, we assessed the whole transcriptome of vaginal cell suspensions from the
macaques in the pilot study using RNA-Seq. Enrichment analysis was performed using the Fisher’s exact test on significantly differential gene expression (FDR < 0.05) between IFN-β-treated vs. control macaque data sets, without an arbitrary cutoff in fold-change.\(^{18,19}\) We first applied transcriptional modules published by Chaussabel \textit{et al.}\(^ {20}\) as broad filters to organize the enrichment results (IFN-β-treated versus controls) into top biologically relevant modules with a single-multivariate score (Figure 4a). Notably, the top five-enriched biological modules by nominal \(P\) value via this method were interferon inducible genes (Module 3.1), inflammation I (Module 3.2), two myeloid cell lineage modules (Module 1.5 and 2.10), and neutrophils (M2.2). As expected, delineation of interferon inducible genes into type 1 or type 2 IRGs using published filters\(^ {21}\) revealed a higher enrichment in type 1 \(\left( P = 2.19 \times 10^{-57} \right) \) vs. type 2 \(\left( P = 4.43 \times 10^{-41} \right)\) associated IRGs with IFN-β treatment (Supplementary Table S1).

Figure 1. Absolute counts of CD4+ T cells (a,b), macrophages, and neutrophils (c) in the vagina of macaques vaginally dosed with IFN-β compared with saline-treated controls. Figures a and b were generated using immunohistochemically stained frozen tissue sections of vagina and show the CD4+ T-cell density in controls \((n = 2)\), vs. increasing concentrations (from left to right) as low dose \((6 \times 10^5 \text{U ml}^{-1}) = \text{LO INF-β, intermediate dose (3} \times 10^6 \text{U ml}^{-1}) = \text{INTERM INF-β}, and high dose \((3 \times 10^6 \text{U ml}^{-1}) = \text{HI INF-β (n = 2) treated rhesus macaques. Sections were analyzed to count cells in the vaginal epithelium (Epi) and lamina propria (LP) combined (a), as well as the epithelium alone (b). At least 10 measurements of each tissue type were measured from each macaque as indicated by individual data points. TCellNumber/EpiArea refers to the number of target cells divided by the area of the epithelium analyzed. \(n\) = number of animals per condition. Each dot represents each individual image analyzed under each condition. Error bars represent standard errors of the mean (s.e.m.). ** \(P < 0.01\) and *** \(P < 0.001\), respectively. (c) Absolute numbers of macrophages (black bars) and neutrophils (white bars) were generated from immunohistochemically stained sections of formalin fixed, paraffin embedded tissue sections and are expressed as numbers of cells per mm\(^2\) tissue for each individual macaque.

Table 1 Expression of inflammatory markers on vaginal T cells in macaques vaginally dosed with IFN-β

| T cell | Marker | Controls | Low dose | Intermediate dose | High dose |
|-------|--------|----------|----------|------------------|-----------|
| CD4+ T | CD38+ | 22.9 | 19.8 | 16.3 | 17.0 | 18.1 | 16.1 | 22.2 | 31.6 |
| | HLA-DR+ | 6.2 | 2.8 | 13.1 | 15.3 | 13.6 | 15.2 | 10.8 | 12.4 |
| | CD38+/HLA-DR+ | 1.1 | 0.7 | 1.6 | 1.5 | 1.6 | 1.7 | 1.9 | 2.2 |
| | CCR5+ | 24.0 | 17.9 | 50.9 | 42.9 | 38.7 | 45.2 | 33.1 | 21.6 |
| | HLA-DR+/CCR5+ | 2.5 | 0.9 | 7.8 | 9.6 | 9.3 | 11.2 | 5.7 | 7.1 |
| | Caspase 3+ | 0.8 | 0.8 | 18.9 | 22.5 | 18.7 | 34.4 | 13.9 | 17.2 |
| | Caspase 3+/CCR5+ | 0.3 | 0.2 | 11.0 | 10.7 | 6.2 | 17.2 | 5.1 | 4.9 |
| CD8+ T | CD38+ | 41.9 | 23.7 | 29.6 | 35.6 | 30.3 | 26.3 | 31.8 | 47.0 |
| | HLA-DR+ | 5.5 | 2.5 | 14.5 | 15.5 | 13.2 | 14.9 | 11.5 | 16.6 |
| | CD38+/HLA-DR+ | 1.8 | 0.5 | 2.8 | 4.2 | 2.9 | 3.3 | 3.8 | 5.9 |
| | CCR5+ | 38.9 | 23.5 | 59.5 | 48.7 | 41.7 | 56.2 | 47.5 | 35.0 |
| | HLA-DR+/CCR5+ | 2.9 | 0.9 | 10.6 | 10.2 | 9.0 | 11.1 | 6.7 | 9.5 |
| | Caspase 3+ | 1.5 | 2.0 | 49.0 | 49.5 | 40.7 | 49.5 | 32.5 | 52.2 |
| | Caspase 3+/CCR5+ | 0.8 | 0.8 | 26.8 | 23.7 | 17.4 | 27.4 | 15.3 | 17.3 |

Numbers indicate percentages of CD4+ or CD8+ T-cell subsets co-expressing the marker(s) indicated on vaginal cells as detected by flow cytometry.
We next conducted a Kegg pathway-based analysis. Kegg pathways are a collection of manually curated and drawn pathway mappings that allow a more specific assessment of potential biology following a supervised contrast than module analysis. The top 10 Kegg pathways enriched in differential gene expression between IFN-β and control treatment ranged from proinflammatory cytokine and cytokine receptor interaction (CXCL1/10/11, CCL23/7/8, IL1β, IL6, IL8, IL10, TNF and IFNγ), toll-like receptor (TLR) signaling and complement activation, to JAK/STAT, WNT, and T-cell signaling activation (Figure 4b). The chemokines identified may promote accumulation of T cells and monocytes into the FRT as observed histologically (Figure 1).

In conclusion, since RNA-Seq was performed on unfractonated single cell suspensions, we employed an adaptation of a recent bioinformatic approach to deconvolute expression data from bulk cells into cell subset-specific subprofiles via published classifier lists.22 We discovered that gene expression changes in FRT of IFN-β-treated macaques occurred predominantly in association with a monocyte subset classifier list. Indeed, monocytes were the only significantly enriched (P = 2.11 × 10−19) classifier, populated by many of the genes mentioned above (IRGs, chemokines, proinflammatory cytokines, and complement; Supplementary Table S2). These data were consistent with the marked increase in macrophage recruitment evident by immunohistochemical analysis (Figure 1c). Although the numbers of animals examined for immunologic changes in tissues were small, combined, these data indicate topical IFN-β was inducing a balanced local protective antiviral host defense response countering proinflammatory cytokine and chemokine activation, despite an increased influx of target cells for SHIV infection.

**DISCUSSION**

Understanding the balance between inflammatory responses that may enhance or prevent HIV transmission in local tissues is a high priority for HIV vaccine and prevention strategies. Type 1 interferons bind to a common receptor expressed on numerous cell types and activate hundreds of cellular genes including genes encoding proteins with antiviral activity. Systemic application of type 1 interferon in rhesus macaques delays simian immunodeficiency virus (SIV) infection, yet sustained administration of this agent during chronic infection comes at the cost of increased immune activation, CD4 T-cell losses and increased viral reservoir size.2 Numerous IRGs limit viral replication including RNaseL, Eukaryotic initiation factor 2 which inhibits viral translation, APOBEC3G, Trim-5α, and tetherin, factors recognized to restrict HIV replication; several that encode IFN-induced proteins with tetratricopeptide repeat, and numerous others which have a variety of roles in mediating antiviral responses. Here we tested the hypothesis that the immune activation induced by topical interferon administration would be overcome by interferon-induced protection against SHIV acquisition. This appeared to be the case, suggesting that IFN-β is arming local mucosal defenses to protect against vaginal SHIV transmission, a model supported by demonstrating IFN-β-induced upregulation of numerous IRGs including IRGs with defined antiviral activity.

Interestingly, however, we also found that topical administration of IFN-β increased numbers of tissue macrophages and CD4+ T-cells expressing CCR5 and HLA-DR, suggesting IFN-β promotes influx of activated cells potentially susceptible to HIV infection. As IFN-β dramatically upregulated the expression of CCL3 (promoting T-cell chemotaxis via CCR5 ligation) and also CXCL10 and CXCL11 (which promote T-cell chemotaxis via binding to CXCR3) we suspect these and other interferon-induced chemokines promote accumulation of target CD4 T cells into the vagina. Nonetheless, despite an increased availability of viral target cells, topical IFN-β was clearly associated with protection from SHIV challenge, likely through stimulation of innate immune defenses. In fact, the increase in myeloid (macrophage) recruitment into tissues may conceivably limit local viral replication and infection by phagocytosis and destruction of locally activated, infected T cells, but this remains speculative. To prevent interference with
vaginal transmission, samples were not acquired from the animals in the challenge studies. However, the significant level of protection observed, combined with data from the pilot study indicating both an influx of macrophages and T cells (in all six treated animals) combined with the RNA-Seq data indicating increases in monocyte activation genes, all suggest that IRGs and innate immune responses had a role in this protection.

This targeted, topical approach may avoid the systemic consequences of sustained systemic interferon exposure. Earlier studies exploring the role of innate defenses in protection from SIV infection attempted to induce these defenses through topical application of TLR ligands including imiquimod (a ligand for TLR 7) and CpG oligodeoxynucleotides (ligands for TLR 9). These studies not only failed to confer protection against SIV challenge but also induced a "storm" of inflammatory mucosal cytokines that were associated with increases in SIV replication in the infected animals.23 We considered the possibility that interferon-independent effects of TLR ligation might have obscured a potentially protective effect of type 1 interferons, and designed these experiments with this in mind. Thus we were able to examine directly the effects of interferon activity on susceptibility to SHIV infection.

The human type 1 interferon family includes several interferons that each bind the same type 1 interferon receptor but with distinguishable effects on downstream signaling.12 We chose β interferon for these studies as in preliminary studies; this interferon was one of several type 1 interferons with the most consistent ability to block HIV replication in human lymphocytes (not shown) and because a recombinant form suitable for parenteral (systemic) administration (Rebif) was commercially available. Further, human and macaque IFN-β proteins are 95% identical and 97% similar by BLAST,24 so we felt confident in using this would be suitable for the macaque studies.

The role of type 1 interferons in HIV disease is not well understood, but sustained replication of both pathogenic HIV and SIV is associated with increased type 1 interferon production25 and systemic administration of type 1 interferon to HIV-infected persons can attenuate the magnitude of HIV replication.26 Recent studies in the rhesus SIV model indicate that blockade of type 1 interferon activity accelerates mortality in infected animals and that systemic administration of type 1 interferon may protect animals from SIV infection.2 HIV-infected persons in whom HIV replication has been controlled with combination antiretroviral therapy also have a profound signature of type 1 interferon exposure and this is most prominent among those who have failed to normalize circulating CD4 T-cell numbers.27 Also, in chronic SIV infection of rhesus macaques, sustained administration of type 1 interferon results in both interferon desensitization, an increase in SIV reservoirs and accelerated CD4 T-cell losses.2 These works suggest that the effects of type 1 interferon are complex in HIV and SIV infections, providing both antiretroviral activity and in some settings, accelerating pathogenesis. Nonetheless, here we show that topical administration of

| Module                                      | Nom. P value | Genes                                                                 |
|---------------------------------------------|-------------|----------------------------------------------------------------------|
| M_3.1_interferon_inducible                 | 2.67237E-46 | ISG15, IFI16, CMPK2, OAS2, R5AD2, OAS1, MX1, IFI1, IFI44L, CXCL10, HERC5, PIP1, HERC6, DDX60, SAMHD1, XAF1, S7AT1, DDX60L, DDXX8, JNP2F13, DTX1, MT1X, R572, PLC1, UY66, LAF3, SAMO9, JRE316, PARP7A, FKRO3, PRCC283, SP110, PH55, LGALS3BP, TRIM22, PARP12, SAM, DAA5, SH5, SAS, TDRD7, NML, STAT2 |
| M_3.2_inflammation_1                       | 5.96503E-08 | CCL3, PEC, CSAR1, IL1B, SERPINB2, ICAM1, VEGFA, SPHK1, NLRP3, IL8, TREM1, CICL2, SPAG5, B3GNT13, D2M, UPP1, H4K2, LMP1, WDR44, LIL |
| M_1.5_myeloid_macrophage_dendritic         | 7.48692E-07 | CD163, CD14, SLC1A3, AIF1, TNFSF13B, TRM2, CTS8, FCN1, IGF5, GRN, BCKDK, GMZ |
| M_2.10_inflammatory_interleukin             | 6.85245E-05 | CSF1R, CYBB, FAM276P, RNASE6, CTSS, MPEG1, GNB84, SAMHD1 |
| M_2.1_neutrophils                           | 0.032045479 | SLPI, DLR1, CAMP |

Figure 4. Top biological modules (a) and pathways (b) induced in vaginal cells after IFN-β treatment. (a) Marked upregulation of interferon inducible genes as well as genes associated with inflammation, and myeloid/macrophage activation were detected. (b) Checkerboard figure presents enrichment analysis of differential gene expression in FRT from IFN-β vs. control macaques. The top 10 enriched Kegg pathways are plotted top to bottom on the y axis and the gene members contributing to the enrichment are plotted along the x axis. The scale represents log2-fold changes with red corresponding to most upregulated and blue to most downregulated genes.
type 1 interferon can protect against pathogenic SHIV challenge. In these experiments, a very high dose of interferon was necessary to provide protection, likely reflecting the need for high concentrations of agents to penetrate vaginal mucosal tissues.28 Thus the costs of IFN-β as a topical strategy to prevent HIV acquisition may be too high to be clinically applicable, but developing a topical prevention strategy is not the crux of this study. A major objective of this study was to begin to delineate specific immune mechanisms and conditions that may be elicited by vaccines or other prevention strategies that result in protective host defenses. Although we did not examine sufficient numbers animals to definitively identify the mechanisms involved in this protection, our findings suggest the possibility that modulation of innate defenses, as reflected by the activity of type 1 interferons shown here, might have a role in the apparent “natural” resistance to HIV infection that has been reported in numerous high-risk exposed populations29 and that other strategies that enhance these endogenous innate defenses might prove to be of value in protection against HIV acquisition. Although we have clearly show a protective associated with topical vaginal IFN-β application, additional studies with larger numbers of animals and more frequent vaginal fluid and biopsy sampling will be needed to specifically determine the molecular mechanisms of protection elicited in the vaginal vault following IFN-β treatment.

Type 1 interferons comprise a large family of innate antiviral defense molecules that can be induced by a variety of microbial elements including viruses and their genetic sequences.29 Type 1 interferons bind to a common receptor expressed on numerous cell types and activate hundreds of cellular genes including genes encoding certain proteins with antiviral activity;30 yet at mucosal sites of challenge with the SIV, the kinetics of interferon induction by exposure to TLR ligands was too delayed to provide sufficient protection from experimental infection.31 It is not unreasonable to propose, therefore, that there may be population variability in the induction, regulation, and activities of such a complex defense network and to this point, a polymorphism near the gene for a type 2 interferon (interferon lambda-3, IL28B) has been linked to variability in the outcome of hepatitis C virus infection both spontaneously and with treatment using a type 1 interferon plus ribavirin.32,33 Upregulation of the activities of cellular RNaseL and downregulation of Eukaryotic initiation factor 2 a by type 1 interferon plus ribavirin and APOBEC3G, Trim-5a, tetherin, SAMHD1, and SLFN11 that more selectively restrict the replication of lentiviruses such as HIV.15 The importance of APOBEC3G, tetherin, and SAMHD1 in antiviral defense is underscored by the existence of HIV and SIV proteins, specifically VIF, VPU, and VPX, respectively, that block their antiviral activities.34–37 Although human Trim-5a does not block HIV replication very effectively, certain non-human primate homologs do38 and small changes in the human sequences result in potent restriction of HIV replication.39 In one small study, higher levels of TRIM-5a RNA were found in PBMC from high-risk persons who escaped HIV infection than in PBMC from persons who were infected.40 A single-nucleotide polymorphism in the APOBEC3G gene (C49693T) has been associated in one study with an increased risk for HIV acquisition.41 Conceivably, other genetic variants in these restriction factors confer variable degrees of protection from infection.

In summary, these results demonstrate that repeated dosing with IFN-β results in a protective state in the vaginal environment that resists repeated vaginal challenge with a pathogenic SHIV, despite increased local accumulation of activated T cells and macrophages and heightened T-cell expression of the HIV co-receptor CCR5. These results suggest that immune activation is not always deleterious and that mucosal protection against HIV acquisition may be achieved by induction of local innate host defenses. The conditions of our experiments do not allow us to identify the optimal duration of interferon exposure necessary for protection; we do not know if shorter exposure to interferon is sufficient for a similar level of protection or if longer application of interferons might confer greater protection. In these experiments, a very high dose of interferon was necessary to provide protection, likely reflecting the need for high concentrations of agents to penetrate vaginal mucosal tissues.28 Thus the costs of IFN-β as a topical strategy to prevent HIV acquisition may be too high to be clinically practicable. Nonetheless, our findings suggest the possibility that modulation of innate defenses, as reflected by the activity of type 1 interferon shown here, might have a role in the apparent ‘natural’ resistance to HIV infection reported in numerous high-risk exposed populations9 and that vaccine or other prevention strategies that enhance these endogenous innate defenses might prove to be of value in protection against HIV acquisition.

Despite decades of research, correlates of protection from HIV infection remain elusive, especially in mucosal tissues. Unique among all viruses, HIV is teaching us hard-learned lessons, in that vaccines or topical microbicides that trigger specific types of inflammatory immune responses may in fact increase, rather than prevent HIV transmission.42,43 Intensive work is focused on delineating the specific immune determinants that increase HIV transmission rates. However, if we could also identify specific patterns of inflammatory or immunosuppressive genes and proteins that provided protection in mucosal surfaces, perhaps these could be explored in HIV prevention trials as surrogate markers for protection, or correlated with protection in those patients who appear to repeatedly resist infection.

METHODS

Animals and experimental design. Adult, healthy female rhesus macaques free of SIV and simian D retrovirus were initially used to assess the immunologic effects of topically administered IFN-β on vaginal mucosal tissues in vivo (n = 6). Vaginal biopsies were assessed by polychromatic flow cytometry and histopathology, and then an additional 34 female macaques (20 treated and 14 controls) were used to assess the protective effects of repeated IFN-β vaginal application followed by vaginal RT-SHIV challenge. All animals were housed at
the Tulane National Primate Research Center in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care International standards, and in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals. All studies were reviewed and approved by the Tulane University Institutional Animal Care and Use Committee.

**Dose ranging topical IFN-β pilot study.** In the first pilot experiment, eight female macaques were intravaginally dosed with 2 ml saline containing either a low dose (1.2 × 10^5 units ml^-1; n = 2), intermediate dose (6 × 10^5 units ml^-1; n = 2) or high dose (3 × 10^6 units ml^-1; n = 2) of recombinant human IFN-β (Rebiq) and two animals were vaginally inoculated with saline only as controls. Two days later macaques were again vaginally dosed with 2 ml IFN-β using the same concentrations as above for each animal. Six hours after this vaginal dosing, all eight animals were humanely euthanized. Portions of vagina and endocervix were collected in complete Roswell Park Memorial Institute medium supplemented with 5% heat inactivated fetal calf serum, l-glutamine, penicillin, streptomycin, and HEPEs) buffer for immediate processing into single cell suspensions for flow cytometry, and adjacent sections were preserved in optimum cutting temperature compound and snap frozen in dry-ice-cooled 2-methylbutane and processed for immunohistochemistry as described below. Parallel tissue sections were formalin fixed for paraffin embedding and sectioning for routine histopathology and immunohistochemistry.

**Tissue processing and isolation of vaginal cells for flow cytometry and RNA-Seq.** Single cell suspensions of vaginal tissues were prepared as previously described. In brief, tissues were cut into 0.5 cm pieces with paired razor blades, and incubated with 1 ml EDTA in Hanks balanced salt solution for 30 min with rapid shaking (300 r.p.m.) in an incubated orbital shaker at 37°C, followed by 2–3 sequential 30 min incubations in complete Roswell Park Memorial Institute medium containing 20 U ml^-1 collagenase (Type I, Sigma, St Louis, MO) again with rapid shaking at 37°C. After each incubation, tissues were further disrupted by gently pipetting 5–10 times with a 16-gauge-feeding needle, pelleted (400 g, 7 min), and supernatants discarded and medium replaced. At the end of these incubations, cell pellets were resuspended and filtered through nylon mesh and layered over a 35%/60% bilayer Percoll density cushion and centrifuged at 1,000 g for 30 min. The interface between the 35 and 60 Percoll layers was collected, washed, and adjusted to 10^7 cells ml^-1. For flow cytometry, 100 μl aliquots (10^7 cells) were stained with appropriately diluted concentrations of monoclonal antibodies to CD3 (SP34), CD4 (L200), CCR5 (L243), HIV-1 Nef (M102) and T-cell receptor for α and β (Invitrogen, San Diego, CA), and CD38 (provided by the NIH Non-human Primate Reagent Resource), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Grand Island, NY), Isotype-matched controls were included in all experiments. Samples were resuspended in BD Stabilizing Fixative (BD Biosciences) and acquired on an LSR-II flow cytometer (Becton Dickinson, San Jose, CA). Data were analyzed with FlowJo software (Tree Star, Ashland, OR).

**Immunohistochemistry and quantitative image analysis.** Immunohistochemistry for CD4 detection was performed on frozen tissue sections. Fresh sections of vagina tissues were embedded and snap frozen in optimum cutting temperature compound in dry-ice-cooled 2-methylbutane. Frozen sections were then prepared from optimum cutting temperature compound blocks using a cryostat, adhered to glass slides, and tissue sections were fixed in 3.7% formaldehyde in piperazine-N,N’-bisethanesulfonic acid (PIPES) buffer and blocked with normal donkey serum before staining. To identify target cells, rhesus macaque tissue was stained with anti-CD4 (Biologend, cat#317422). Images were obtained by deconvolution microscopy on a DeltaVision RT system collected on a digital camera (CoolSNAP HQ; Photometrics) using × 60 oil objective. To determine the target cell density in individual macaque sections, at least 10 measurements of vaginal samples were examined per macaque. The area of the epithelium was calculated from the stratum basale to the lumen using DeltaVision SoftWoX software intraepithelial target cell densities were assessed for each individual sample. To assess CD4+ cells in the lamina propria (below the stratum basale), additional area measurements were expanded to include the epithelium and ~20 μm past the basal layer. Overall, for both data sets, each image consisted of a stitched panel comprised of two ×60 images across the lumen and n × 60 images past the basal layer, n being dependent on the epidermal thickness of each individual sample. Per animal, 10 panel images, consisting of 3 panels across and n panels into the epithelium (n dependent on the thickness of the epithelium as this varied among animals) were taken. To calculate the density of each sample, the number of target cells in each sample was divided by the average area of the epithelium or epithelium plus ~20 μm past the stratum basale, respectively. Data are expressed as numbers of CD4+ T cells divided by the total area of the tissue analyzed in Figures 1a,b.

**Immunohistochemistry and image analysis of macrophages and neutrophils in vaginal tissues was assessed on formalin fixed, paraffin embedded tissue sections which were de-paraffinized and hydrated. Antigen retrieval was performed in a Decloaking Chamber (Biocare Medical, Concord, CA), at 125°C and 25ºC. Endogenous peroxidase activity was blocked with buffered hydrogen peroxide (Biocare Medical) for 5 min at room temperature (RT). Unspecific binding of Abs was blocked using purified casein and other proteins (Background Sniper, Biocare Medical) for 10 min at RT. Slides were incubated with the following primary Abs for 1 h at RT: mouse monoclonal anti-human CD68 (clone KP1, Dako, Carpinteria, CA), mouse monoclonal anti-human neutrophil defensins (clone D21, Leica Biosystems, Buffalo Grove, IL). Anti-mouse EnVision + Systems horseradish peroxidase was used for 45 min at RT as a secondary Ab and visualization was performed using a DAB + (diaminobenzidine) substrate chromogen (Dako). Sections were counterstained with hematoxylin, dehydrated, and mounted in mounting medium. Slides were scanned using a Zeiss MIRAX MIDI slide scanner in the brightfield mode. Cell counts were performed using HistoQuest analysis software (TissueGnostics). Nuclei were first segmented based on their hematoxylin nuclear stains. Then, intensity of colorimetric stain was determined within a defined radius of each cell nucleus and reported as cells per mm² as shown in Figure 1c.

**Viral challenge experiments.** In the first series of challenge experiments, 15 female macaques were intravaginally dosed with 2 ml of medium containing either the high dose (3 × 10^6 U ml^-1; n = 6), or the low dose (1.2 × 10^5 U ml^-1; n = 5) of IFN-β, or saline placebo (n = 5) to match the dose ranging experiments above. Exactly 4 h later, all 15 animals were intravaginally challenged with 300 TCID50 of RT-ShIVsf162P3 (ref. 45) obtained from the NIH AIDS Reagent Program. One and two days (24 and 48 h) after initial dosing, vaginal IFN-β or placebo dosing was repeated. This dosing and challenge regimen was repeated weekly for 5 weeks. Blood was collected weekly to determine if animals were protected or infected after challenge. In these and subsequent challenge studies, no vaginal tissues were collected to ensure integrity of the FRT, and not interfere with viral challenges and infectivity. In subsequent experiments, the low-dose IFN-β group was omitted, and a total of 10 additional macaques were vaginally dosed with 2 ml of 3 × 10^6 U ml^-1 IFN-β and 9 controls were dosed with placebo, followed 4 h later by pathogenic challenge with RT-ShIVsf162P3. Vaginal IFN-β and placebo treatments were repeated 24 and 48 h later, exactly as in the second experiment above (no FRT samples collected). Data shown in Figure 2 only includes the 15 animals treated with the high-dose IFN-β and the 14 controls.

**RNA-Seq and data analysis.** RNA was isolated from the vaginal cells from two treated and two control macaques using RNeasy Micro spin columns (Qiagen, Germantown, MD) and measured for quality using a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). All samples had a RIN score between 7 and 9.6 (average: 8.7). Sequencing libraries...
were prepared with TruSeq RNA v2 kits (Illumina, San Diego, CA) using the manufacturer’s standard protocols. Library quality was assessed by measuring insert size using a Bioanalyzer 2100 (average size: 323.6 bp) and library concentration determined by quantitative PCR (Library Quantification Kit, KR0405, Kapa Biosystems, Wilmington, MA). The libraries were run on a HiSeq 2500 with 50 bp paired end reads (average reads per sample: 13.68 million). Reads were trimmed of Illumina adapter sequences using Trimmomatic v0.32.46 Trimmmed paired end reads were mapped against the macaque genome (MMUL 1.0, v78) using the STAR aligner v2.3.0e.47 Transcript abundances were estimated using HTSeq v0.6.1.48 The count matrices (ref. 49) and Student’s t-test. Given the small data set, the genes with P value and false discovery rate (FDR) <0.05 were then tested for enriched pathways using Fisher’s exact test (P<0.05 significance level).

Supplementary Material is linked to the online version of the paper at http://www.nature.com/mi.

ACKNOWLEDGMENTS
We thank Terri and Kelsi Rasmussen, Megan Gardner, Meagan Watkins, and Maury Duplantis and Marina Krybaeva for technical assistance. We also thank Stephanie Richards and Andrew Smith at the VGTI Florida Collaborative Genomics Center for performing the RNA-Seq assays. The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: RT Envi SHIV Virus P244 derived (PHA), from Dr James Smith. This work was supported in part by NIH grants U19 AI076981, R01 AI084793, the National Center for Research Resources, and the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health through grant no. OD01104-51, and the Center for AIDS Research at Case Western Reserve University (AI08219).

DISCLOSURE
The authors declare no conflict of interest.

© 2016 Society for Mucosal Immunology

REFERENCES
1. Tomescu, C., Abdulhaqq, S. & Montaner, L.J. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin. Exp. Immunol. 164, 158–169 (2011).
2. Sandler, N.G. et al. Type I Interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).
3. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856–1862 (1996).
4. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).
5. Sarmon, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).
6. Lederman, M.M. et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485–487 (2004).
7. Veazey, R.S. et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 199, 1525–1537 (2009).
8. Veazey, R.S. et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202, 739–744 (2010).
9. Lederman, M.M. et al. Determinants of protection among HIV-exposed seronegative persons: an overview. J. Infect. Dis. 202, S333–S338 (2010).
10. Salkowitz, J.R. et al. Characterization of high-risk HIV-1 seronegative hemophilacs. Clin. Immunol. 98, 200–211 (2001).
11. Lane, J. et al. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum. Mol. Genet. 22, 1903–1910 (2013).
12. Randall, R.E. & Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus counter-measures. J. Gen. Virol. 89, 1–47 (2008).
13. van Montfort, N., Olagnier, D. & Hascott, J. Unmasking immune sensing of retroviruses: interplay between innate sensors and host effectors. Cytokine Growth Factor Rev. 25, 657–668 (2014).
14. Tough, D.F. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90, 492–497 (2012).
15. Sperber, S.J., Doyle, W.J., McBride, T.P., Sorrentino, J.V., Riker, D.K. & Hayden, F.G. Otoligic effects of interferon beta serum in experimental rhinovirus colds. Arch. Otolaryngol. Head Neck Surg. 118, 933–936 (1992).
16. Ludwiczek, O., Kaser, A., Koch, R.O., Vogel, W., Cruikshank, W.W. & Tilg, H. Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur. Cytokine Netw. 12, 478–486 (2001).
17. Zipp, F., Beyrer, M., Gelderblom, H., Wernet, D., Zschenderlein, R. & Weller, M. No induction of apoptosis by IFN-beta in human antigen-specific Tcells. Neurology 54, 485–487 (2000).
18. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
19. Tian, L., Greenberg, S.A., Kong, S.W., Altshuler, J., Kohane, I.S. & Park, P.J. Discovering statistically significant pathways in expression profiling studies. Proc. Natl Acad. Sci. USA 102, 13544–13549 (2005).
20. Chassabell, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunology 29, 150–164 (2008).
21. Waddell, S.J. et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 5, e9753 (2010).
22. Nakaya, H.I. et al. Systems biology of vaccine for seasonal influenza in humans. Nat. Immunol. 12, 786–795 (2011).
23. Wang, Y., Abel, K., Lantz, K., Krieg, A.M., McChesney, M.B. & Miller, C.J. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J. Virol. 79, 14355–14370 (2005).
24. Witwer, K.W., Sisk, J.M., Gama, L. & Clements, J.E. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J. Immunol. 184, 2369–2376 (2010).
25. Vanderford, T.H. et al. Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Nature 119, 5750–5757 (2012).
26. Arnouth, D.M. et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1 monoinfected participants: a phase II clinical trial. J. Infect. Dis. 201, 1686–1696 (2010).
27. Fernandez, S. et al. CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J. Infect. Dis. 204, 1927–1935 (2011).
28. Veazey, R.S. et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438, 99–102 (2005).
29. Pichlmaier, A. & Reis e Sousa, C. Innate recognition of viruses. Immunity 27, 370–383 (2007).
30. Der, S.D., Zhou, A., Williams, B.R. & Silverman, R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998).
31. Abel, K., Rocke, D.M., Chohan, B., Fritts, L. & Miller, C.J. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection in highly exposed uninfected individuals with hemophilia A. J. Virol. 83, 15623–15628 (2009).
32. Ge, D. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 399–401 (2009).
33. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 796–801 (2009).
34. Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658–661 (2011).
35. Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* **474**, 654–657 (2011).

36. Malim, M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **364**, 675–687 (2009).

37. Neil, S.J., Zang, T. & Blencowe, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature* **451**, 425–430 (2008).

38. Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P. & Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. *Nature* **427**, 848–853 (2004).

39. Stremlau, M., Perron, M., Welikala, S. & Sodroski, J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. *J. Virol.* **79**, 3139–3145 (2005).

40. Sewram, S. et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV infection. *J. Infect. Dis.* **199**, 1657–1663 (2009).

41. Valcke, H.S., Bernard, N.F., Bruneau, J., Alany, M., Tsoukas, C.M. & Roger, M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. *AIDS* **20**, 1984–1986 (2006).

42. Gray, G.E. et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. *Lancet Infect. Dis.* **14**, 388–396 (2014).

43. Ramjee, G., Govinden, R., Morar, N.S. & Mbebu, A. South Africa’s experience of the closure of the cellulose sulphate microbicide trial. *PLoS Med.* **4**, e235 (2007).

44. Veazey, R.S. et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. *J. Virol.* **74**, 57–64 (2000).

45. Smith, J.M. et al. Generation of a dual RT Env SHIV that is infectious in rhesus macaques. *J. Med. Primatol.* **39**, 213–223 (2010).

46. Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

47. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).

48. Anders, S., Pyl, P.T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

49. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).